NEJM:达比加群在未确定栓塞性卒中病史的患者中的预防作用

2020-04-20 网络 网络

对于来源不确定的栓塞性卒中患者,我们进行了达比加群每天150 mg或110 mg每天两次与阿司匹林100 mg每日一次剂量的多中心,随机,双盲试验。主要结果是卒中复发。主要安全结果是大出血。

对于来源不确定的栓塞性卒中患者,我们进行了达比加群每天150 mg或110 mg每天两次与阿司匹林100 mg每日一次剂量的多中心,随机,双盲试验。主要结果是卒中复发。主要安全结果是大出血。

 

共有5390名患者在564个地点入选,并随机分配接受达比加群(2695例)或阿司匹林(2695例)。在19个月的中位随访期间,达比加群组(每年4.1%)中有177例患者(6.6%)发生复发性中风,阿司匹林组(每年4.8%)中有207例患者(7.7%)发生卒中(危险比率为0.85; 95%置信区间[CI]为0.69至1.03; P = 0.10)。缺血性卒中分别发生于172例患者(每年4.0%)和203例患者(每年4.7%)(危险比,0.84; 95%CI,0.68至1.03)。在达比加群组中有77例患者(每年1.7%)发生大出血,在阿司匹林组中有64例患者(每年1.4%)发生大出血(危险比,1.19; 95%CI,0.85至1.66)。临床相关的非重大出血分别发生在70例患者(每年1.6%)和41例患者(每年0.9%)中。

 

在近期有未确定栓塞性卒中病史的患者中,达比加群在预防复发性卒中方面不优于阿司匹林。达比加群组的大出血发生率不高于阿司匹林组,但达比加群组有更多临床相关的非大出血事件。

 

原始出处:

 

Hans-Christoph DienerRalph L Sacco, et al., Dabigatran for Prevention of Stroke After Embolic Stroke of Undetermined Source. N Engl J Med. 2019 May 16;380(20):1906-1917. doi: 10.1056/NEJMoa1813959.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (29)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=895279, encodeId=bb088952e9e6, content=未确定栓塞性<a href='/topic/show?id=b64035999ca' target=_blank style='color:#2F92EE;'>#卒中#</a>病史的患者中,<a href='/topic/show?id=23959394eda' target=_blank style='color:#2F92EE;'>#达比加群#</a>在预防<a href='/topic/show?id=02cc4252e0f' target=_blank style='color:#2F92EE;'>#复发性卒中#</a>方面不优于<a href='/topic/show?id=51639e734cb' target=_blank style='color:#2F92EE;'>#阿司匹林#</a>,阿司匹林的位置仍然不容易动摇, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35999, encryptionId=b64035999ca, topicName=卒中), TopicDto(id=93947, encryptionId=23959394eda, topicName=达比加群), TopicDto(id=42527, encryptionId=02cc4252e0f, topicName=复发性卒中), TopicDto(id=97734, encryptionId=51639e734cb, topicName=阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Oct 29 09:36:08 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382706, encodeId=63a6382e06ab, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon May 11 07:11:55 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382698, encodeId=97d238269898, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 10 23:42:02 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382661, encodeId=1ca0382661d6, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat May 09 23:41:35 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382628, encodeId=3b8938262876, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri May 08 23:30:39 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382576, encodeId=cc7c3825e6b3, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 07 07:14:27 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382575, encodeId=fc603825e569, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 07 07:14:14 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382566, encodeId=2ab53825665b, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed May 06 23:14:27 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382528, encodeId=5081382528aa, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue May 05 23:39:39 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382493, encodeId=d14638249305, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon May 04 15:33:02 CST 2020, time=2020-05-04, status=1, ipAttribution=)]
    2020-10-29 lovetcm

    未确定栓塞性#卒中#病史的患者中,#达比加群#在预防#复发性卒中#方面不优于#阿司匹林#,阿司匹林的位置仍然不容易动摇

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=895279, encodeId=bb088952e9e6, content=未确定栓塞性<a href='/topic/show?id=b64035999ca' target=_blank style='color:#2F92EE;'>#卒中#</a>病史的患者中,<a href='/topic/show?id=23959394eda' target=_blank style='color:#2F92EE;'>#达比加群#</a>在预防<a href='/topic/show?id=02cc4252e0f' target=_blank style='color:#2F92EE;'>#复发性卒中#</a>方面不优于<a href='/topic/show?id=51639e734cb' target=_blank style='color:#2F92EE;'>#阿司匹林#</a>,阿司匹林的位置仍然不容易动摇, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35999, encryptionId=b64035999ca, topicName=卒中), TopicDto(id=93947, encryptionId=23959394eda, topicName=达比加群), TopicDto(id=42527, encryptionId=02cc4252e0f, topicName=复发性卒中), TopicDto(id=97734, encryptionId=51639e734cb, topicName=阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Oct 29 09:36:08 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382706, encodeId=63a6382e06ab, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon May 11 07:11:55 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382698, encodeId=97d238269898, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 10 23:42:02 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382661, encodeId=1ca0382661d6, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat May 09 23:41:35 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382628, encodeId=3b8938262876, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri May 08 23:30:39 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382576, encodeId=cc7c3825e6b3, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 07 07:14:27 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382575, encodeId=fc603825e569, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 07 07:14:14 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382566, encodeId=2ab53825665b, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed May 06 23:14:27 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382528, encodeId=5081382528aa, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue May 05 23:39:39 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382493, encodeId=d14638249305, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon May 04 15:33:02 CST 2020, time=2020-05-04, status=1, ipAttribution=)]
    2020-05-11 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=895279, encodeId=bb088952e9e6, content=未确定栓塞性<a href='/topic/show?id=b64035999ca' target=_blank style='color:#2F92EE;'>#卒中#</a>病史的患者中,<a href='/topic/show?id=23959394eda' target=_blank style='color:#2F92EE;'>#达比加群#</a>在预防<a href='/topic/show?id=02cc4252e0f' target=_blank style='color:#2F92EE;'>#复发性卒中#</a>方面不优于<a href='/topic/show?id=51639e734cb' target=_blank style='color:#2F92EE;'>#阿司匹林#</a>,阿司匹林的位置仍然不容易动摇, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35999, encryptionId=b64035999ca, topicName=卒中), TopicDto(id=93947, encryptionId=23959394eda, topicName=达比加群), TopicDto(id=42527, encryptionId=02cc4252e0f, topicName=复发性卒中), TopicDto(id=97734, encryptionId=51639e734cb, topicName=阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Oct 29 09:36:08 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382706, encodeId=63a6382e06ab, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon May 11 07:11:55 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382698, encodeId=97d238269898, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 10 23:42:02 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382661, encodeId=1ca0382661d6, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat May 09 23:41:35 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382628, encodeId=3b8938262876, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri May 08 23:30:39 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382576, encodeId=cc7c3825e6b3, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 07 07:14:27 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382575, encodeId=fc603825e569, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 07 07:14:14 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382566, encodeId=2ab53825665b, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed May 06 23:14:27 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382528, encodeId=5081382528aa, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue May 05 23:39:39 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382493, encodeId=d14638249305, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon May 04 15:33:02 CST 2020, time=2020-05-04, status=1, ipAttribution=)]
    2020-05-10 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=895279, encodeId=bb088952e9e6, content=未确定栓塞性<a href='/topic/show?id=b64035999ca' target=_blank style='color:#2F92EE;'>#卒中#</a>病史的患者中,<a href='/topic/show?id=23959394eda' target=_blank style='color:#2F92EE;'>#达比加群#</a>在预防<a href='/topic/show?id=02cc4252e0f' target=_blank style='color:#2F92EE;'>#复发性卒中#</a>方面不优于<a href='/topic/show?id=51639e734cb' target=_blank style='color:#2F92EE;'>#阿司匹林#</a>,阿司匹林的位置仍然不容易动摇, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35999, encryptionId=b64035999ca, topicName=卒中), TopicDto(id=93947, encryptionId=23959394eda, topicName=达比加群), TopicDto(id=42527, encryptionId=02cc4252e0f, topicName=复发性卒中), TopicDto(id=97734, encryptionId=51639e734cb, topicName=阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Oct 29 09:36:08 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382706, encodeId=63a6382e06ab, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon May 11 07:11:55 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382698, encodeId=97d238269898, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 10 23:42:02 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382661, encodeId=1ca0382661d6, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat May 09 23:41:35 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382628, encodeId=3b8938262876, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri May 08 23:30:39 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382576, encodeId=cc7c3825e6b3, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 07 07:14:27 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382575, encodeId=fc603825e569, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 07 07:14:14 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382566, encodeId=2ab53825665b, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed May 06 23:14:27 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382528, encodeId=5081382528aa, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue May 05 23:39:39 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382493, encodeId=d14638249305, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon May 04 15:33:02 CST 2020, time=2020-05-04, status=1, ipAttribution=)]
    2020-05-09 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=895279, encodeId=bb088952e9e6, content=未确定栓塞性<a href='/topic/show?id=b64035999ca' target=_blank style='color:#2F92EE;'>#卒中#</a>病史的患者中,<a href='/topic/show?id=23959394eda' target=_blank style='color:#2F92EE;'>#达比加群#</a>在预防<a href='/topic/show?id=02cc4252e0f' target=_blank style='color:#2F92EE;'>#复发性卒中#</a>方面不优于<a href='/topic/show?id=51639e734cb' target=_blank style='color:#2F92EE;'>#阿司匹林#</a>,阿司匹林的位置仍然不容易动摇, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35999, encryptionId=b64035999ca, topicName=卒中), TopicDto(id=93947, encryptionId=23959394eda, topicName=达比加群), TopicDto(id=42527, encryptionId=02cc4252e0f, topicName=复发性卒中), TopicDto(id=97734, encryptionId=51639e734cb, topicName=阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Oct 29 09:36:08 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382706, encodeId=63a6382e06ab, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon May 11 07:11:55 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382698, encodeId=97d238269898, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 10 23:42:02 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382661, encodeId=1ca0382661d6, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat May 09 23:41:35 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382628, encodeId=3b8938262876, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri May 08 23:30:39 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382576, encodeId=cc7c3825e6b3, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 07 07:14:27 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382575, encodeId=fc603825e569, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 07 07:14:14 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382566, encodeId=2ab53825665b, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed May 06 23:14:27 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382528, encodeId=5081382528aa, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue May 05 23:39:39 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382493, encodeId=d14638249305, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon May 04 15:33:02 CST 2020, time=2020-05-04, status=1, ipAttribution=)]
    2020-05-08 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=895279, encodeId=bb088952e9e6, content=未确定栓塞性<a href='/topic/show?id=b64035999ca' target=_blank style='color:#2F92EE;'>#卒中#</a>病史的患者中,<a href='/topic/show?id=23959394eda' target=_blank style='color:#2F92EE;'>#达比加群#</a>在预防<a href='/topic/show?id=02cc4252e0f' target=_blank style='color:#2F92EE;'>#复发性卒中#</a>方面不优于<a href='/topic/show?id=51639e734cb' target=_blank style='color:#2F92EE;'>#阿司匹林#</a>,阿司匹林的位置仍然不容易动摇, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35999, encryptionId=b64035999ca, topicName=卒中), TopicDto(id=93947, encryptionId=23959394eda, topicName=达比加群), TopicDto(id=42527, encryptionId=02cc4252e0f, topicName=复发性卒中), TopicDto(id=97734, encryptionId=51639e734cb, topicName=阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Oct 29 09:36:08 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382706, encodeId=63a6382e06ab, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon May 11 07:11:55 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382698, encodeId=97d238269898, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 10 23:42:02 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382661, encodeId=1ca0382661d6, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat May 09 23:41:35 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382628, encodeId=3b8938262876, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri May 08 23:30:39 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382576, encodeId=cc7c3825e6b3, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 07 07:14:27 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382575, encodeId=fc603825e569, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 07 07:14:14 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382566, encodeId=2ab53825665b, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed May 06 23:14:27 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382528, encodeId=5081382528aa, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue May 05 23:39:39 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382493, encodeId=d14638249305, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon May 04 15:33:02 CST 2020, time=2020-05-04, status=1, ipAttribution=)]
    2020-05-07 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=895279, encodeId=bb088952e9e6, content=未确定栓塞性<a href='/topic/show?id=b64035999ca' target=_blank style='color:#2F92EE;'>#卒中#</a>病史的患者中,<a href='/topic/show?id=23959394eda' target=_blank style='color:#2F92EE;'>#达比加群#</a>在预防<a href='/topic/show?id=02cc4252e0f' target=_blank style='color:#2F92EE;'>#复发性卒中#</a>方面不优于<a href='/topic/show?id=51639e734cb' target=_blank style='color:#2F92EE;'>#阿司匹林#</a>,阿司匹林的位置仍然不容易动摇, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35999, encryptionId=b64035999ca, topicName=卒中), TopicDto(id=93947, encryptionId=23959394eda, topicName=达比加群), TopicDto(id=42527, encryptionId=02cc4252e0f, topicName=复发性卒中), TopicDto(id=97734, encryptionId=51639e734cb, topicName=阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Oct 29 09:36:08 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382706, encodeId=63a6382e06ab, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon May 11 07:11:55 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382698, encodeId=97d238269898, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 10 23:42:02 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382661, encodeId=1ca0382661d6, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat May 09 23:41:35 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382628, encodeId=3b8938262876, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri May 08 23:30:39 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382576, encodeId=cc7c3825e6b3, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 07 07:14:27 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382575, encodeId=fc603825e569, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 07 07:14:14 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382566, encodeId=2ab53825665b, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed May 06 23:14:27 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382528, encodeId=5081382528aa, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue May 05 23:39:39 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382493, encodeId=d14638249305, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon May 04 15:33:02 CST 2020, time=2020-05-04, status=1, ipAttribution=)]
    2020-05-07 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=895279, encodeId=bb088952e9e6, content=未确定栓塞性<a href='/topic/show?id=b64035999ca' target=_blank style='color:#2F92EE;'>#卒中#</a>病史的患者中,<a href='/topic/show?id=23959394eda' target=_blank style='color:#2F92EE;'>#达比加群#</a>在预防<a href='/topic/show?id=02cc4252e0f' target=_blank style='color:#2F92EE;'>#复发性卒中#</a>方面不优于<a href='/topic/show?id=51639e734cb' target=_blank style='color:#2F92EE;'>#阿司匹林#</a>,阿司匹林的位置仍然不容易动摇, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35999, encryptionId=b64035999ca, topicName=卒中), TopicDto(id=93947, encryptionId=23959394eda, topicName=达比加群), TopicDto(id=42527, encryptionId=02cc4252e0f, topicName=复发性卒中), TopicDto(id=97734, encryptionId=51639e734cb, topicName=阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Oct 29 09:36:08 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382706, encodeId=63a6382e06ab, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon May 11 07:11:55 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382698, encodeId=97d238269898, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 10 23:42:02 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382661, encodeId=1ca0382661d6, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat May 09 23:41:35 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382628, encodeId=3b8938262876, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri May 08 23:30:39 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382576, encodeId=cc7c3825e6b3, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 07 07:14:27 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382575, encodeId=fc603825e569, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 07 07:14:14 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382566, encodeId=2ab53825665b, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed May 06 23:14:27 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382528, encodeId=5081382528aa, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue May 05 23:39:39 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382493, encodeId=d14638249305, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon May 04 15:33:02 CST 2020, time=2020-05-04, status=1, ipAttribution=)]
    2020-05-06 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=895279, encodeId=bb088952e9e6, content=未确定栓塞性<a href='/topic/show?id=b64035999ca' target=_blank style='color:#2F92EE;'>#卒中#</a>病史的患者中,<a href='/topic/show?id=23959394eda' target=_blank style='color:#2F92EE;'>#达比加群#</a>在预防<a href='/topic/show?id=02cc4252e0f' target=_blank style='color:#2F92EE;'>#复发性卒中#</a>方面不优于<a href='/topic/show?id=51639e734cb' target=_blank style='color:#2F92EE;'>#阿司匹林#</a>,阿司匹林的位置仍然不容易动摇, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35999, encryptionId=b64035999ca, topicName=卒中), TopicDto(id=93947, encryptionId=23959394eda, topicName=达比加群), TopicDto(id=42527, encryptionId=02cc4252e0f, topicName=复发性卒中), TopicDto(id=97734, encryptionId=51639e734cb, topicName=阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Oct 29 09:36:08 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382706, encodeId=63a6382e06ab, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon May 11 07:11:55 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382698, encodeId=97d238269898, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 10 23:42:02 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382661, encodeId=1ca0382661d6, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat May 09 23:41:35 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382628, encodeId=3b8938262876, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri May 08 23:30:39 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382576, encodeId=cc7c3825e6b3, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 07 07:14:27 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382575, encodeId=fc603825e569, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 07 07:14:14 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382566, encodeId=2ab53825665b, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed May 06 23:14:27 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382528, encodeId=5081382528aa, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue May 05 23:39:39 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382493, encodeId=d14638249305, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon May 04 15:33:02 CST 2020, time=2020-05-04, status=1, ipAttribution=)]
    2020-05-05 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=895279, encodeId=bb088952e9e6, content=未确定栓塞性<a href='/topic/show?id=b64035999ca' target=_blank style='color:#2F92EE;'>#卒中#</a>病史的患者中,<a href='/topic/show?id=23959394eda' target=_blank style='color:#2F92EE;'>#达比加群#</a>在预防<a href='/topic/show?id=02cc4252e0f' target=_blank style='color:#2F92EE;'>#复发性卒中#</a>方面不优于<a href='/topic/show?id=51639e734cb' target=_blank style='color:#2F92EE;'>#阿司匹林#</a>,阿司匹林的位置仍然不容易动摇, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35999, encryptionId=b64035999ca, topicName=卒中), TopicDto(id=93947, encryptionId=23959394eda, topicName=达比加群), TopicDto(id=42527, encryptionId=02cc4252e0f, topicName=复发性卒中), TopicDto(id=97734, encryptionId=51639e734cb, topicName=阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Oct 29 09:36:08 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382706, encodeId=63a6382e06ab, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon May 11 07:11:55 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382698, encodeId=97d238269898, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 10 23:42:02 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382661, encodeId=1ca0382661d6, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat May 09 23:41:35 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382628, encodeId=3b8938262876, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri May 08 23:30:39 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382576, encodeId=cc7c3825e6b3, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 07 07:14:27 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382575, encodeId=fc603825e569, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 07 07:14:14 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382566, encodeId=2ab53825665b, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed May 06 23:14:27 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382528, encodeId=5081382528aa, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue May 05 23:39:39 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382493, encodeId=d14638249305, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon May 04 15:33:02 CST 2020, time=2020-05-04, status=1, ipAttribution=)]
    2020-05-04 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

相关资讯

BMC Neurol:中国成人卒中后会及时叫救护车吗?

由于健康行为随着年龄的增长而变化,本研究旨在研究40-74岁和75-99岁的成年人在认识到中风后呼叫紧急医疗服务(EMS)的潜在障碍。

Stroke:健康男性体重变化与卒中和死亡的长期风险

健康男性青年时体重增加,而不是中年体重增加,与卒中的长期风险增加有关。如果这些结果能够得到证实,那么预防体重增加的努力应该针对年轻人群。

Stroke:步行速度与卒中发病率之间的关系

在这项以人群为基础的队列研究中,64岁以上的参与者步行速度慢与较高的卒中风险有关。在初级保健或公共卫生临床咨询中增加自我报告步行速度这一指标可能是一个有用的卒中风险筛查工具。

BMJ:亚急性脑卒中患者的健康训练效果如何?

本研究旨在探讨有氧运动对卒中后亚急性期患者日常生活活动的安全性和有效性。采用多中心、随机对照、终点双盲试验设计,在德国7个住院康复中心(2013-17年)进行。

ACC: 疫情期间,心梗和卒中患者要及时就医!欧美心脏学会呼吁

目前,受新冠病毒疫情影响,全球很多国家到医院就诊的心肌梗死或中风的病人数量大幅下降。

Stroke:21世纪高收入国家卒中发病率的趋势

在牛津郡和其他高收入地区,脑卒中发病率持续下降,并保持稳定。然而,卒中患者的绝对数量并没有下降。